FAS: PRICES FOR A NUMBER OF MEDICINES HAVE BEEN REDUCED BY AN AVERAGE OF 30%

21-12-2021 | 18:02

In accordance with the rules of state registration and re-registration of prices for vital medicines (VED)*, in some cases, pharmaceutical companies must independently submit applications for price reduction. For example, when a manufacturer, after registering or re-registering the price of a medicine in Russia, reduces its cost abroad or if the first reproduced medicine loses its price advantage after the second and subsequent ones enter the market.

FAS controls the timeliness of submitting relevant applications from manufacturers. In case they do not submit an application, FAS issues a notification to the pharmaceutical company about the need to reduce the cost of the medicine. The manufacturers have 20 working days to reduce the price or give a written reasoned justification for the set price. Otherwise, FAS is obliged to make a decision to cancel the registered price, after which the sale of the medicine is prohibited at all stages of treatment.

This year, as part of the monitoring of medicine prices, FAS sent 21 notifications of a decrease in 51 registered maximum selling prices for VED**. For example, the cost of the in-demand medicine Lisinopril used for arterial hypertension, after reducing the marginal registration price by an average of 37%, decreased in pharmacies in Moscow from 196 rubles to 104 rubles (for the 5 mg release form No. 28) and from 760 rubles to 495 rubles (for the 20 mg release form No. 56).

FAS continues to monitor the fulfillment of the obligation to reduce the cost of medicines included in the list in these cases by manufacturers.

Reference:

*Included in the Decree of the Government of the Russian Federation dated 29.10.2010 №. 865 (ed. dated 18.11.2020) “On the State Regulation of Prices for Medicines Included in the List of Vital and Essential Medicines”.

**According to the results, pharmaceutical companies have reduced their prices by an average of 30%. Manufacturers provided justifications for the existing prices for 4 medicines. Prices for 4 more medicines were excluded from the register: for one of them - at the initiative of the manufacturer, for three more - due to the cancellation of prices by the service due to their non-reduction in due time.



Site Map

News & Events Press Releases Media Releases Image Library About the FAS Russia What We Do Institutional Memory Mission, Goals, Values Priority Setting Stakeholders Engagement Center for Education and Methodics Our History Our Structure Powers of Head and Deputy Heads Our Ratings Global Competition Review Using our website International Cooperation Treaties & Agreements OECD Competition Committee OECD meetings 2013 OECD meetings 2014 OECD meetings 2015 OECD meetings 2016 OECD meetings 2017 OECD meetings 2018 OECD meetings 2019 OECD meetings 2020 OECD meetings 2021 FAS Annual Reports OECD-GVH RCC RCC Newsletter ICAP Council on Advertising Headquarters for Joint Investigations UNCTAD 15th session IGE UNCTAD 16th session IGE UNCTAD 17th session IGE UNCTAD 18th session IGE UNCTAD 8th UN Conference on Competition 19th session IGE UNCTAD EEU Model Law on Competition ICN BRICS BRICS Conferences Documents The BRICS Competition Law and Policy Centre (BRICS Competition Centre) BRICS Working Groups for the research of competition issues in socially important markets The Working Group for Research on the Competition Issues in the Pharmaceutical Markets Chair: Russia The Working Group for Research on food value chains Chair: South Africa The Working Group for Research on the Competition Issues in the Automobile Markets Co-chaired: India, South Africa The Working Group for Research on the Competition Issues in the Digital Markets Co-chairs: Brazil, Russia BRICS Coordination Committee on antimonopoly policy EU APEC Competition Policy and Law Group Annual meetings Projects ERRA Full Members Organizational Structure Archive Working Group on Investigating Issues on Pricing in the Oil and Oil Product Markets and Methods of their Functioning Meetings Working Group for Studying Competition Problems in the Pharmaceutical Sector Working Group on Research of Competition Issues in the Market of International Telecommunications (Roaming) Document Library Legislation Reports & Analytics Cases & decisions COVID-19 Contacts Give feedback Contact us Links Authorities Worldwide